Q4'24 expectations
For the end of the year we expect OssDsign to have continued to improve its market access, both by adding more hospitals as customers and by increasing penetration in the existing customer base by getting more surgeons to use the product. We forecast Q4'24 sales of SEK 37.0m, up 38% y-o-y adjusted for the discontinued business and up 4% q-o-q compared to Q3'24. The ramp-up in sales could be lumpy between quarters, but we expect to see a continued positive sales trajectory on a trailing 12-months basis over the coming years. As OssDsign continues to ramp up sales and aims to increase market penetration, we expect a sequential increase in opex to SEK 48.0m (vs. SEK 44.2m in Q3'24). Looking at earnings, we forecast EBIT of SEK -13.2m in Q4e, driven by a gross margin of 94.0%.
Aktuellt
SENASTE
